Educational Activities Archives

hotspot_textonly
Filter by Target Audience

Please select the option that best aligns with your profession.

Target Audience
hotspot_textonly
Filter by Topic

Please select the option that best aligns with your topic of interest.

Click on the plus (+) icon to display subtopics.

hotspot_textonly
Filter by Format

Please select the option that best aligns with your preferred format of training.

Formats
hotspot_textonly
Key Term Search

Use the search bar to enter in the title of a training, or other key terms.

Back to Filter ^

Medical Considerations for Patients with Opioid Use Disorder

Format: Module
This module reviews features of skin and soft tissue infections among people who inject drugs, reviews risk factors for Hepatitis C (HCV) and HIV, describes prevention interventions for HCV and HIV, and discusses treatment approaches for HCV and HIV in patients with opioid use disorder.
View Activity
Target Audience(s):
Interprofessional Teams, Nurses, PAs, Pharmacists, Physicians, Students and Educators
Topic(s):
Co-Occurring SUD / Medical Disorders, Cardiovascular, Ethics, General Medical Comorbidities, Hepatic, Infectious Disease, Stigma, SUD Core Curriculum, Supplemental ...
Presenter(s):
Jeanette M. Tetrault, MD, FACP, FASAM, Professor of Medicine and Public Health, Yale School of Medicine
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Creditâ„¢, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Organizer(s):
American Academy of Addiction Psychiatry

Integrating Care: The Role of MOUD in Addressing Opioid Use Disorder and Infectious Disease

Format: Webinar
Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.
View Activity
Target Audience(s):
Administrative Staff, Counselors, Family and Patient, Interprofessional Teams, Nurses, PAs, Pharmacists, Pharmacy Technicians, Physicians, Psychiatrists, Psychologists, Social Workers, Students and Educators
Topic(s):
Co-Occurring SUD / Medical Disorders, ASAM Criteria, Assessment, Buprenorphine, Cardiovascular, Emergency Setting, Endocrine and Metabolic, General Medical Comorbidities, Hepatic, Hospital Setting ...
Presenter(s):
Daniel Rosa, MD
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Organizer(s):
National Council for Mental Wellbeing

Hepatitis C – FAQs, Statistics, Data, & Guidelines

Format: Clinical Tool
CDC Guidances and Resources
View Activity
Target Audience(s):
Nurses, Family and Patient, Physicians, Psychiatrists, Psychologists, Social Workers
Topic(s):
Co-Occurring SUD / Medical Disorders, General Medical Comorbidities, Hepatic ...
Credit Available:
CE Credit(s): No
Certificate: No

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers

Format: Clinical Tool
View the Abstract.
View Activity
Target Audience(s):
PAs, Physicians, Psychiatrists, Students and Educators
Topic(s):
Co-Occurring SUD / Medical Disorders, General Medical Comorbidities, Hepatic, Hospitalist ...
Credit Available:
CE Credit(s): No
Certificate: No

Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone

Format: Clinical Tool
How should I monitor liver function tests in patients who are receiving naltrexone or extended-release naltrexone for their treatment of opioid and or alcohol use disorders? What should I do if a patient receiving naltrexone does develop evidence of a severe elevation of liver function tests or acute hepatitis?
View Activity
Target Audience(s):
Physicians, Psychiatrists
Topic(s):
Co-Occurring SUD / Medical Disorders, Alcohol, General Medical Comorbidities, Hepatic, Infectious Disease, Medications, Naltrexone, Naltrexone, Opioids, Treatment ...
Credit Available:
CE Credit(s): No
Certificate: No

Monitoring of Liver Function Tests and Hepatitis in Patients Receiving Buprenorphine/Naloxone

Format: Clinical Tool
How should I monitor liver function tests in patients with or without underlying chronic hepatitis who are receiving buprenorphine for the treatment of opioid dependence? What should I do if a patient receiving buprenorphine does develop evidence of acute hepatitis or worsening chronic hepatitis?
View Activity
Target Audience(s):
Physicians, Psychiatrists
Topic(s):
Co-Occurring SUD / Medical Disorders, Buprenorphine, General Medical Comorbidities, Hepatic, Infectious Disease, Medications, Opioids, Treatment ...
Credit Available:
CE Credit(s): No
Certificate: No
More Results